Venus Concept Stock Soars 127% Premarket After Regaining Nasdaq Compliance
As part of the compliance, Venus Concept will be under a mandatory panel monitor until June 4, 2025.
This Pharma Stock Dropped 60% Premarket As FDA Halted Diabetes Drug Trials
Elevated liver enzyme levels were noted, although most adverse events were mild to moderate, with no severe reactions reported.
Tevogen Bio Confirms Ongoing Efficacy Of TVGN 489 Against Dominant FLiRT Strains Of SARS-CoV-2
Tevogen Bio Holdings Inc. ("Tevogen" or "Tevogen Bio") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology,
Scilex Holding Company Announces FDA Approval For Commercial Manufacturing Of Gloperba, A Prophylactic Treatment For Gout Flares In Adults, To Launch June 10, 2024
Gloperba® is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.Gout is a painful arthritic disorder affecting an estimated 9.2
First Human Death From Bird Flu Strain Puts Vaccine Stocks Back On The Map
Moderna shares are up almost 29% this month; CureVac is up 72% in the past month; and Novavax spiked 317% in the past month.
Some Breather For E-Cigarette Maker Juul As FDA Reconsiders Marketing Denials Issued Two Years Ago
FDA rescinds marketing denial orders for JUUL Labs Inc., pending further review. Recent case law influences decision. FDA seeks scientific soundness in e-cigarette approval process. JUUL's financial woes continue amid regulatory uncertainty.
Italy Probes European Pharma Giants Novartis, Roche Over Eye Drug Competition Allegations
Italy's antitrust authority is investigating Novartis and Roche's Genentech for allegedly delaying the Italian market launch of Byooviz, a Samsung Bioepis biosimilar of Lucentis.
AbbVie’s Immunogen Acquired Elahere Meets Primary Goal In Mid-Stage Study In Heavily Pretreated Ovarian Cancer Patients
AbbVie announced Phase 2 PICCOLO trial results for Elahere in heavily pre-treated ovarian cancer patients. The trial achieved a 51.9% objective response rate.
Why Is 4D Molecular Therapeutics Stock Trading Lower On Thursday? Genetic Disease-Focused Study Data Released
4D Molecular Therapeutics shares interim data from the 4D-710 Phase 1/2 AEROW clinical trial for cystic fibrosis lung disease.
Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday?
Replimune reported that the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma showed a 33.6% response rate, with all responses lasting over six months. The treatment was well-tolerated.